Skin cancer represents a broad classification of malignancies, which can be further refined by histology, including basal cell carcinoma, squamous cell carcinoma and melanoma. As these three cancers are distinct entities, we review each one separately, with a focus on their epidemiology, etiology including relevant genomic data, and the current evidence-based recommendations for adjuvant and neoadjuvant therapy. We also discuss future directions and opportunities for continued therapeutic advances.
Keywords: Adjuvant; Basal cell carcinoma; Checkpoint inhibitors; Cutaneous squamous cell carcinoma; Hedgehog inhibitor; Melanoma; Neoadjuvant; Systemic therapy.
Published by Elsevier Inc.